Emergent BioSolutions Inc.
- Open
- 6.23
- Day high
- 6.50
- Day low
- 6.23
- Prev close
- 6.22
- Volume
- 1.0M
- Mkt cap
- $331M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 1.0
- P/S
- 0.4
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$25K over the last 3 months (0 open-market buys, 1 sale)
- 🏛Institutions accumulating (13F)
Emergent BioSolutions Inc. (EBS) is a Healthcare company listed on NYSE. The stock is down 18% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 1 sale (SEC Form 4). Drillr has 2 published research articles covering EBS.
Emergent BioSolutions Inc. (EBS) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
EBS earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 5, 2026 | $-0.09 | $0.60 | +805.9% | $234M | +32.0% |
| Apr 30, 2026 | $-0.25 | $0.21 | +184.0% | $156M | +7.7% |
| Oct 29, 2025 | $-0.12 | $1.06 | +983.3% | $231M | +6.3% |
| Mar 3, 2025 | $-0.35 | $0.05 | +114.3% | $189M | -32.2% |
| May 1, 2024 | $-0.86 | $0.59 | +168.6% | $300M | +58.1% |
| Mar 6, 2024 | $-0.33 | $-0.77 | -133.3% | $277M | -5.8% |
| Dec 11, 2023 | — | $-1.76 | — | $331M | — |
| Feb 27, 2023 | — | $-1.76 | — | $331M | — |
| Apr 28, 2022 | — | $-0.07 | — | $308M | — |
| Feb 24, 2022 | $4.27 | $4.50 | +5.4% | $723M | +7.7% |
| Nov 4, 2021 | — | $-0.65 | — | $329M | — |
| Jul 29, 2021 | $1.81 | $0.33 | -81.8% | $398M | -2.6% |
EBS insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 2, 2026 | Williams Paul Anthonyofficer: SVP, Products Business | Sell | 3,000 | $8.40 |
| Jun 10, 2026 | Williams Paul Anthonyofficer: SVP, Products Business | Tax | 694 | $8.00 |
| Jun 10, 2026 | Glessner Coleenofficer: EVP, Quality & Ethics, and CPL | Tax | 2,018 | $8.00 |
| Jun 10, 2026 | LINDAHL RICHARD Sofficer: EVP, Chief Financial Officer | Tax | 3,964 | $8.00 |
| Jun 10, 2026 | Hartzel Williamofficer: SVP, Bioservices | Tax | 1,741 | $8.00 |
| May 4, 2026 | Katkin Keithdirector | Sell | 15,481 | $8.28 |
| May 4, 2026 | White Marvin Ldirector | Grant | 25,344 | — |
| May 4, 2026 | Fowler Neal Franklindirector | Grant | 25,344 | — |
| May 4, 2026 | Richard Ronalddirector | Grant | 11,296 | $7.99 |
| May 4, 2026 | Katkin Keithdirector | Grant | 25,344 | — |
| May 4, 2026 | Richard Ronalddirector | Grant | 25,344 | — |
| May 4, 2026 | Dayal Sujata Tyagidirector | Grant | 25,344 | — |
| May 4, 2026 | Zoon Kathryn Cdirector | Grant | 25,344 | — |
| May 4, 2026 | DeGolyer Donald Wdirector | Grant | 11,296 | $7.99 |
| May 4, 2026 | DeGolyer Donald Wdirector | Grant | 25,344 | — |
Source: EBS SEC Form 4 filings, latest Jul 2, 2026. For informational purposes only — not investment advice.
See the full EBS insider & 13F page →EBS research & analysis
EBS: FY25 Deep Dive
Emergent BioSolutions FY25 at $743M. NI $53M; EPS $0.93.
Vaccine Procurement Shifts From Outbreak Awards to Standing Budgets
Bavarian Nordic, SIGA, Emergent and Valneva told August 2026 calls that sovereign and multilateral budgets, not outbreak awards, now drive vaccine orders.
206650.KQBVNKFGOVX
Emergent BioSolutions Inc. company profile
Overview
Emergent BioSolutions Inc. (NYSE:EBS) is a specialized life sciences company founded in 1998 and headquartered in Gaithersburg, Maryland. The company went public in 2006 and has evolved into a leading provider of medical countermeasures and emergency response solutions for public health threats. Emergent focuses on addressing chemical, biological, radiological, nuclear, and explosive threats, as well as emerging infectious diseases and opioid overdose emergencies. The company has undergone significant strategic transformation in recent years, streamlining operations and focusing on its core competencies in biodefense and overdose prevention.
Business
Emergent BioSolutions operates in the specialized pharmaceutical sector, focusing on medical countermeasures and emergency response therapeutics. The company's business is divided into three main segments: 1. Commercial Products segment (~40% of revenue): This segment is dominated by NARCAN Nasal Spray, a naloxone-based nasal spray used for emergency treatment of known or suspected opioid overdoses. NARCAN is a life-saving medication that can reverse the effects of opioid overdoses by blocking opioid receptors in the brain. The product is distributed through both over-the-counter retail channels and public interest programs to first responders, schools, and community organizations. 2. Medical Countermeasures (MCM) segment (~45% of revenue): This segment includes vaccines and treatments for biodefense threats. Key products include BioThrax (anthrax vaccine), ACAM2000 (smallpox vaccine), Botulism Antitoxin Heptavalent, and various other countermeasures for biological warfare agents. These products are primarily sold to government agencies, particularly the U.S. Department of Health and Human Services and Department of Defense, as part of national preparedness initiatives. 3. Services segment (~15% of revenue): This includes contract development and manufacturing organization (CDMO) services, providing drug substance manufacturing, packaging, technology transfer, and analytical development services to other pharmaceutical companies. The company also markets additional specialized vaccines including Vivotif (oral typhoid vaccine) and Vaxchora (oral cholera vaccine), along with various investigational products in development for emerging health threats.
Revenue model
Emergent BioSolutions generates revenue through multiple business models tailored to its diverse product portfolio and customer base. The company primarily makes money through direct product sales to government agencies and commercial distribution channels, along with service fees from contract manufacturing. For its Medical Countermeasures business, Emergent operates on a government contract model, where it receives large, multi-year procurement contracts from agencies like the Biomedical Advanced Research and Development Authority (BARDA) and the Centers for Disease Control and Prevention (CDC). These contracts often include milestone payments and can range from tens of millions to hundreds of millions of dollars. The government serves as the primary customer, purchasing these products for national stockpiles and emergency preparedness. The Commercial Products segment, led by NARCAN, operates through a dual-channel distribution model. Approximately 70% of NARCAN sales come from public interest programs where state and local governments, NGOs, and healthcare systems purchase the product using federal funding, opioid settlement money, and grant programs. The remaining 30% comes from over-the-counter retail sales through pharmacies and direct-to-consumer channels. Revenue growth is influenced by several key factors. Positive drivers include increasing government investment in biodefense preparedness, the ongoing opioid crisis driving NARCAN demand, international expansion opportunities, and potential new product approvals. Margin pressures come from generic competition (particularly for NARCAN), government pricing negotiations, manufacturing complexity and regulatory compliance costs, and the cyclical nature of government procurement cycles. The company's margins are also affected by its manufacturing footprint optimization efforts and the need to maintain expensive specialized facilities for biodefense products.
Competitive moat
Emergent BioSolutions operates in a highly specialized niche with several defensive characteristics, though its moat strength varies by business segment. In the Medical Countermeasures space, the company benefits from significant regulatory barriers and specialized manufacturing requirements. Developing vaccines and treatments for biodefense threats requires extensive FDA approval processes, specialized containment facilities, and deep expertise in handling dangerous pathogens. The government customer base values established relationships and proven track records, creating switching costs. However, this moat is somewhat narrow as it depends heavily on government funding priorities and contract renewals. For NARCAN, Emergent's competitive position is more vulnerable. While the company currently holds approximately 75% market share in naloxone nasal sprays and benefits from strong brand recognition and established distribution networks, the product faces increasing generic competition. The company's first-mover advantage and extensive distribution relationships provide some protection, but naloxone is not patent-protected as a molecule, making it susceptible to generic erosion over time. The company's manufacturing capabilities provide some competitive advantages, particularly its specialized facilities for handling live pathogens and its regulatory compliance track record. However, these assets are also costly to maintain and require continuous investment. Overall, Emergent operates in a defensive but narrow moat business. The specialized nature of biodefense creates barriers to entry, but the heavy dependence on government contracts and the cyclical nature of preparedness spending limit the durability of competitive advantages. The company's transformation strategy aims to diversify revenue streams and reduce this concentration risk.
Risks & safety
Emergent BioSolutions presents a moderate margin of safety profile with improving but still elevated financial risks: **Liquidity and Solvency:** - Cash position: $149 million as of Q1 2025, improved from $99.5 million in Q4 2024 - Current ratio: 6.32x indicating strong short-term liquidity - Debt-to-equity ratio: 1.20x, significantly improved from peak levels above 2.0x - Net leverage reduced from 5.7x to 2.8x through debt reduction efforts **Valuation Metrics:** - Price-to-earnings ratio: 0.97x (based on Q1 2025 positive earnings) - Price-to-book ratio: 0.48x suggesting potential undervaluation - EV/EBITDA: 1.47x (Q1 2025) indicating attractive valuation multiples - Graham number: $16.90 vs. current price around $6.36 **Other Considerations:** - Free cash flow turned positive in Q3 2024 ($147.9M) but negative in Q1 2025 (-$14.8M), showing volatility - Company completed major restructuring with $130M+ in annual cost savings - Revenue guidance of $750-850M for 2025 provides visibility - Dependence on government contracts creates revenue concentration risk
Recent development
Over the past few years, Emergent BioSolutions has undergone a comprehensive strategic transformation focused on stabilization and operational efficiency. The company initiated a multi-year turnaround plan that included significant workforce reductions (approximately 50% since January 2024), facility consolidations, and streamlined operations. Key facility closures included the Rockville and Bayview sites, with operations concentrated in Lansing and Winnipeg to achieve over $130 million in annualized cost savings. The company has made substantial progress in debt reduction and financial restructuring. Net debt was reduced by over $200 million in 2024, and the company refinanced its debt structure with a new $250 million term loan and $100 million revolving credit facility. The net leverage ratio improved dramatically from 5.7x to 2.8x, significantly strengthening the balance sheet. NARCAN expansion has been a major strategic focus, with the successful launch of over-the-counter sales in August 2023. The company expanded distribution to over 32,000 retail outlets and developed new B2B channels targeting workplaces and first-aid applications. Recent developments include a significant 3-year, $65 million agreement with Ontario province and the acquisition of commercial rights to KLOXXADO, a higher-dose naloxone nasal spray for fentanyl overdoses. In the Medical Countermeasures space, Emergent achieved important regulatory milestones including FDA approval for ACAM2000's Mpox indication and continued progress on products like CYFENDUS anthrax vaccine. The company has also focused on international expansion, donating doses to African countries and exploring global market opportunities. Recent leadership changes include the appointment of Dr. Simon Lowry as Head of R&D and Chief Medical Officer to strengthen the product development pipeline.
EBS company profile · for informational purposes only — not investment advice.
Track EBS with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free